The investment more than doubles manufacturing capacity for cytokines, growth factors, and other critical materials used in cell and gene therapy production.
The second Lansing facility will add superconducting linear accelerator capacity to support growing demand for radiopharmaceuticals used in targeted cancer therapies.
